DOI QR코드

DOI QR Code

Efficacy of Ecabet Sodium for Helicobacter pylori Eradication with Sequential Therapy

순차치료에 병합 투여된 Ecabet Sodium이 Helicobacter pylori 제균에 미치는 효과

  • So, Seol (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Ji Yong (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Na, Hee Kyong (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Kee Wook (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jeong Hoon (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Do Hoon (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Kee Don (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Ho June (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Gin Hyug (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Hwoon-Yong (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine)
  • 소설 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 안지용 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 나희경 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 정기욱 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 이정훈 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 김도훈 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 최기돈 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 송호준 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 이진혁 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 정훈용 (울산대학교 의과대학 서울아산병원 소화기내과)
  • Received : 2018.04.14
  • Accepted : 2018.06.08
  • Published : 2018.09.30

Abstract

Background/Aims: We aimed to compare the outcomes of Helicobacter pylori eradication in patients receiving sequential therapy (ST) depending on the use of ecabet sodium (ES). Materials and Methods: Between January to December 2015, 176 patients randomly received either ST alone (n=72) or 10-day ES therapy combined with ST (n=104). After applying the exclusion criteria, 56 patients were finally assigned to the ST-only group and 84 to the ST with ES group. We retrospectively reviewed and analyzed the H. pylori eradication rate and adverse events between the two groups. Results: Among the 140 patients, 121 (86.4%) achieved successful H. pylori eradication and 24 (17.1%) had adverse events. Eradication was achieved in 50 patients (89.3%) in the ST-only group and in 71 patients (84.5%) in the ST with ES group (P=0.420). No significant difference in the incidence of adverse events was found between the ST-only and ST with ES groups (12.5% vs. 20.2%, respectively; P=0.234). However, the ST with ES group tended to have a higher prevalence of nausea or vomiting than the ST-only group (11.9% vs. 1.8%; P=0.050). Conclusions: ST showed a good H. pylori eradication rate without deteriorating the adverse events regardless of adding ES.

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI)

References

  1. Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 2013;13:104. https://doi.org/10.1186/1471-230X-13-104
  2. Shin WG, Lee SW, Baik GH, et al. Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter 2016;21:266-278. https://doi.org/10.1111/hel.12279
  3. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26. https://doi.org/10.4166/kjg.2013.62.1.3
  4. Choi JM, Kim SG. Diagnosis and treatment of Helicobacter pylori infection: Korean and overseas guidelines. Korean J Med 2015;89:157-168. https://doi.org/10.3904/kjm.2015.89.2.157
  5. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. https://doi.org/10.1136/gutjnl-2016-312288
  6. Chang JY, Shim KN, Tae CH, et al. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. https://doi.org/10.1186/s12876-017-0579-8
  7. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013;37:647-650. https://doi.org/10.1016/j.clinre.2013.04.003
  8. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004;19:407-414. https://doi.org/10.1046/j.1365-2036.2004.01818.x
  9. Kagaya H, Kato M, Komatsu Y, et al. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther 2000;14:1523-1527. https://doi.org/10.1046/j.1365-2036.2000.00852.x
  10. Shibata K, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M. Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 1995;39:1295-1299. https://doi.org/10.1128/AAC.39.6.1295
  11. Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A, Sugawara K. Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. J Gastroenterol 2001;36:153-157. https://doi.org/10.1007/s005350170122
  12. Adachi K, Ishihara S, Hashimoto T, et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2001;15:1187-1191. https://doi.org/10.1046/j.1365-2036.2001.01022.x
  13. Kim HW, Kim GH, Cheong JY, et al. H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008;14:908-912. https://doi.org/10.3748/wjg.14.908
  14. Heo J, Jeon SW. Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2014;63:141-145. https://doi.org/10.4166/kjg.2014.63.3.141
  15. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206-214. https://doi.org/10.1111/hel.12031
  16. Chan CC, Chien NH, Lee CL, et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. https://doi.org/10.1186/s12876-015-0401-4
  17. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63:748-752. https://doi.org/10.1099/jmm.0.072322-0
  18. Liou JM, Chen CC, Chang CY, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-1792. https://doi.org/10.1136/gutjnl-2015-310142
  19. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-931. https://doi.org/10.7326/0003-4819-148-12-200806170-00226
  20. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005;21:1419-1424. https://doi.org/10.1111/j.1365-2036.2005.02519.x
  21. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-325.
  22. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-1277. https://doi.org/10.1016/S0016-5085(98)70100-3
  23. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100. https://doi.org/10.7326/0003-4819-144-2-200601170-00006
  24. Roh SH, Shim KN. The effect of probiotics for Helicobacter pylori. Korean J Helicobacter Up Gastrointest Res 2011;11:26-36. https://doi.org/10.7704/kjhugr.2011.11.1.26
  25. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-2749. https://doi.org/10.1111/j.1572-0241.2002.07063.x
  26. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-168.
  27. Hayashi S, Sugiyama T, Yokota K, et al. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol Immunol 2000;44:557-562. https://doi.org/10.1111/j.1348-0421.2000.tb02534.x
  28. Koizumi W, Tanabe S, Nakatani K, et al. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 2010;35:303-307.
  29. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-268. https://doi.org/10.1111/j.1523-5378.2008.00601.x
  30. Kim JM, Kim JS, Jung HC, Oh YK, Kim N, Song IS. Inhibition of Helicobacter pylori-induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Helicobacter 2003;8:542-553. https://doi.org/10.1046/j.1523-5378.2003.00175.x
  31. Shimoyama T, Fukuda Y, Fukuda S, Munakata A, Yoshida Y, Shimoya T. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol 1996;31(Suppl 9):59-62.
  32. Seo JY, Kim MJ, Ko KH, Kim DH, Lim DS, Chon HR. Efficacy of ecabet sodium for Helicobacter pylori eradication, combined with lansoprazole-based triple regimen: a prospective study. Korean J Med 2011;80:546-552.